Slide 1: Co-Dx
Slide 2: Forward Looking Statement
conti Forward Looking Statement THESE MATERIALS CONTAIN FORWARD-LOOKING STATEMENTS THAT INVOLVE SIGNIFICANT RISKS AND. UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPECTED. THERE CAN BE NO ASSURANCE THAT ANY ANTICIPATED RESULTS WILL OCCUR ON A TIMELY BASIS OR AT AL
Slide 3: Ebola kills fast. Detection must move faster.
Ebola kills fast. an / wart Detection must move faster. Bin A ~4f , ITURI Case fatality rate 48.3% Nearly half of confirmed % 28 health zones patients have died. Epicenter of the outbreak 4,802 of 5,794 cases (82.9%) reported in tur, B O TSHOPO 5 off 6 157 Confirmed cases health zones — y ft eer Rep
Slide 4: The biggest health challenges are solved at the point of need
£3 Co-Dx°* | ReadyGo Bringing together the Co-Dx PCR Platform Th e bi g g est point-of-need PCR technology, and GoCollect® by ReadyGo, field capable sample health challenges preparation technology, to advance a new approach to decentralized Ebola detection and outbreak response. aria t solved Prepar
Slide 5: GoCollect by ReadyGo
GoCollect® by ReadyGo PREPARE. Prepare a blood sample for PCR or molecular testing at the point of need. GoCollect® by ReadyGo prepares blood samples for molecular testing through integrated sample conditioning and plasma separation. @ coLtect+conpmion Capillary blood collection with integrated samp
Slide 6: The Co-Dx PCR Platform: Detect
Ebola Response The Co-Dx eoolaResponse PCR Platform DETECT. Demecratic Bring molecular detection closer Repub of to where outbreaks happen. 7 EBOLA POSITIVE CASES TESTS PERFORMED 1,256 4 128% ia simulated and doce ro! Gold-Standard PCR Point-of-Care Testing High-quality molecular Testing closer to w
Slide 7: Prepare. Detect. Respond.
Prepare. Detect. Respond. ee | Ee ay RESPOND Real-time information with Co-Dx Cloud PREPARE DETECT Blood-based Sample PCR Detection at the Preparation point-of-need
Slide 8: Manufacturing
Manufacturing MANUAL PRODUCTION AUTOMATED 6 ‘ xo Higher throughput. Consistent quality Amore scalable future 30.47 sec > sec Cycle time Cycle time (Manual) (Automated) 757 > (Per Shift) (Projected) Cups produced Cups produced (Manual) (Automated) |_| Manual Automated
Slide 9: Slide 9
Slide 10: India Region Market Size
India Region-Market Size Diagnostic Market Size Estimates $11.4B Current estimated 5 diagnostic market size g e for the India region & a g e Ss 7 jd ladesh inglades| $1.68 is | $134.0M $49.9M $40.1M ma ——— = India Bangladesh Pakistan Sri Lanka Nepal ~4.9 trillion 8.5% Expanding GDP in the India regi
Slide 11: India Update: The Market Has Been Validated
INDIA UPDATE The Market Has Been Validated. Decentralized molecular diagnostics are gaining global adoption — and investor attention. ~$105B 70x 12,500+ 90+ IPO valuation IPO oversubscribed devices deployed countries PCR Pro’ is built for this market. s2 Co-Dx % = ane Simple. Accessible. Connected.
Slide 12: MTB Clinical Studies
wo | MTB Clinical Studies Validating the complete decentralized MTB workflow in one of the world’s highest-burden TB markets. 1. SAMPLE 2. LYSIS 3.PCR PRO 4. MTB RESULT Swabbed sputum or tongue Heat-kill sample prep Multiplex real-time PCR On mobile app and cloud => CLINICAL SITES COMPLETE WORKFLOW
Slide 13: India Update: Building capability
INDIA UPDATE Building capability. Expanding in-house capabilities that strengthen PCR Pro® and create commercial opportunities. F LN X a Ty P. s Hose f; WN —— ; nl — 5 IN-HOUSE MASTER MIX AND EXTRACTION KIT OLIGONUCLEOTIDE PRODUCTION SAMPLE PREPARATION Supporting CoSara assays with In-house synthesi
Slide 14: The breakthrough isn't PCR. It's where PCR can go.
The breakthrough isn’t PCR. It’s where PCR can go. Bringing gold-standard molecular diagnostics closer to where they’re needed most. 2, ray Co-Dx SS $ co-px | = a